The positive impact on translational research of Fondazione italiana di ricerca per la Sclerosi Laterale Amiotrofica (AriSLA), a non-profit foundation focused on amyotrophic lateral sclerosis. Convergence of ex-ante evaluation and ex-post outcomes when goals are set upfront.
ALS research
RCR
amyotrophic lateral sclerosis
relative citation ratio
research assessment
Journal
Frontiers in research metrics and analytics
ISSN: 2504-0537
Titre abrégé: Front Res Metr Anal
Pays: Switzerland
ID NLM: 101718019
Informations de publication
Date de publication:
2023
2023
Historique:
received:
12
10
2022
accepted:
14
07
2023
medline:
21
8
2023
pubmed:
21
8
2023
entrez:
21
8
2023
Statut:
epublish
Résumé
Charities investing on rare disease research greatly contribute to generate ground-breaking knowledge with the clear goal of finding a cure for their condition of interest. Although the amount of their investments may be relatively small compared to major funders, the advocacy groups' clear mission promotes innovative research and aggregates highly motivated and mission-oriented scientists. Here, we illustrate the case of Fondazione italiana di ricerca per la Sclerosi Laterale Amiotrofica (AriSLA), the main Italian funding agency entirely dedicated to amyotrophic lateral sclerosis research. An international benchmark analysis of publications derived from AriSLA-funded projects indicated that their mean relative citation ratio values (iCite dashboard, National Institutes of Health, U.S.) were very high, suggesting a strong influence on the referring international scientific community. An interesting trend of research toward translation based on the "triangle of biomedicine" and paper citations (iCite) was also observed. Qualitative analysis on researchers' accomplishments was convergent with the bibliometric data, indicating a high level of performance of several working groups, lines of research that speak of progression toward clinical translation, and one study that has progressed from the investigation of cellular mechanisms to a Phase 2 international clinical trial. The key elements of the success of the AriSLA investment lie in: (i) the clear definition of the objectives (research with potential impact on patients, no matter how far), (ii) a rigorous peer-review process entrusted to an international panel of experts, (iii) diversification of the portfolio with
Identifiants
pubmed: 37601533
doi: 10.3389/frma.2023.1067981
pmc: PMC10436489
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1067981Informations de copyright
Copyright © 2023 Guareschi, Ravasi, Baldessari, Pozzi, Zaffino, Melazzini and Ambrosini.
Déclaration de conflit d'intérêts
SG, MR, TZ, MM, and AA were employed by the company Fondazione AriSLA ETS. DB, SP, and AA were employed by the company Fondazione Telethon ETS.
Références
Semin Ophthalmol. 2022 Jul 4;37(5):539-540
pubmed: 35695556
J Neurosurg. 2020 Jan 31;134(2):638-645
pubmed: 32005024
Lancet Neurol. 2012 Apr;11(4):323-30
pubmed: 22406228
Neuron. 2020 Dec 9;108(5):822-842
pubmed: 32931756
Nat Med. 2022 Oct;28(10):1985-1988
pubmed: 35970921
EMBO Rep. 2021 May 5;22(5):e51740
pubmed: 33738926
Dis Model Mech. 2017 May 1;10(5):537-549
pubmed: 28468939
Nat Rev Neurol. 2021 Feb;17(2):104-118
pubmed: 33340024
Physiol Meas. 2019 Apr 04;40(3):034004
pubmed: 30840931
Medicine (Baltimore). 2018 Jun;97(24):e11119
pubmed: 29901635
J Med Libr Assoc. 2018 Oct;106(4):508-513
pubmed: 30271298
Nat Commun. 2020 Apr 14;11(1):1773
pubmed: 32286313
J Biol Chem. 2012 Mar 2;287(10):7512-25
pubmed: 22235134
Neurobiol Dis. 2020 May;138:104792
pubmed: 32027933
Brain. 2021 Dec 31;144(12):3710-3726
pubmed: 34972208
J Neurol Neurosurg Psychiatry. 2015 Aug;86(8):879-86
pubmed: 25595151
Prog Neurobiol. 2020 Jul;190:101803
pubmed: 32335272
Sci Rep. 2018 Feb 5;8(1):2378
pubmed: 29402919
Ergonomics. 2012;55(5):538-51
pubmed: 22455372
PLoS One. 2014 Jan 30;9(1):e86720
pubmed: 24497973
Brain. 2021 Oct 22;144(9):2635-2647
pubmed: 33905493
Lancet Neurol. 2019 Feb;18(2):155-164
pubmed: 30554828
EJNMMI Res. 2020 Mar 23;10(1):23
pubmed: 32201914
Nat Neurosci. 2014 May;17(5):664-666
pubmed: 24686783
Br J Pharmacol. 2022 Apr;179(8):1732-1752
pubmed: 34783031
Ann Clin Transl Neurol. 2022 Nov;9(11):1692-1701
pubmed: 36259277
J Transl Med. 2013 May 24;11:126
pubmed: 23705970
Nature. 2012 Aug 23;488(7412):499-503
pubmed: 22801503
Sci Rep. 2018 Jul 4;8(1):10105
pubmed: 29973608
Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16569-72
pubmed: 16275915
Nat Commun. 2017 Mar 30;8:14741
pubmed: 28358055
Mol Cell. 2016 Sep 1;63(5):796-810
pubmed: 27570075
Genes Dev. 2012 Aug 1;26(15):1679-84
pubmed: 22855830
Amyotroph Lateral Scler Frontotemporal Degener. 2013 Dec;14(7-8):546-52
pubmed: 23834069
N Am Spine Soc J. 2022 Jul 14;11:100143
pubmed: 35928806
BMC Biol. 2020 Mar 26;18(1):34
pubmed: 32216790
PLoS Biol. 2016 Sep 06;14(9):e1002541
pubmed: 27599104
Neuroimage Clin. 2017 Aug 02;16:240-247
pubmed: 28794983
iScience. 2020 May 22;23(5):101087
pubmed: 32371370
Eur J Neurol. 2020 Oct;27(10):1918-1929
pubmed: 32526057
EMBO J. 2011 Jan 19;30(2):277-88
pubmed: 21131904
PLoS One. 2016 Apr 28;11(4):e0154404
pubmed: 27124610
Neurobiol Dis. 2014 Nov;71:95-109
pubmed: 25088713
Cell Stress Chaperones. 2018 Jan;23(1):1-12
pubmed: 28608264
Neurology. 2020 Nov 3;95(18):e2552-e2564
pubmed: 32913015
Mol Biol Cell. 2017 Jun 1;28(11):1401-1408
pubmed: 28559438
FASEB J. 2019 Oct;33(10):10780-10793
pubmed: 31287959
PLoS Biol. 2019 Oct 10;17(10):e3000416
pubmed: 31600189
Sci Rep. 2017 May 17;7(1):2033
pubmed: 28515487
Nat Cell Biol. 2019 Oct;21(10):1286-1299
pubmed: 31570834
Neuron. 2018 Mar 21;97(6):1268-1283.e6
pubmed: 29566793
Amyotroph Lateral Scler Frontotemporal Degener. 2022 May;23(3-4):203-208
pubmed: 34151660
J Neurol. 2015 May;262(5):1376-8
pubmed: 25893256
Brain. 2018 Aug 1;141(8):2272-2279
pubmed: 30730551
N Engl J Med. 2022 Sep 22;387(12):1099-1110
pubmed: 36129998
PLoS Biol. 2019 Oct 10;17(10):e3000385
pubmed: 31600197
Front Physiol. 2019 Jul 10;10:897
pubmed: 31354530
J Cell Sci. 2021 Mar 22;134(6):
pubmed: 33558311
J Neurosci. 2017 Feb 8;37(6):1413-1427
pubmed: 28011744
Dis Model Mech. 2013 Jul;6(4):869-70
pubmed: 23690539